Prevalence of Thrombophilic Gene Polymorphism (MTHFR C677T) in COVID-19patients

Study Overview
=================
Brief Summary
-----------------
Aim of the study is to find the prevalence of thrombophilic gene methylene tetrahydrofolate reductase (MTHFR) gene polymorphism in a sample of COVID-19 patients, aiming at early detection of MTHFR mutant patients and guiding preventive therapy.

Detailed Description
-----------------
The inflammatory component of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) creates a prothrombotic state that necessitates a thrombophylactic strategy for hospitalized patients. Such strategies are difficult to be standardized because certain individuals can have prothrombotic conditions, such as inherited thrombophilia, which predispose them to an additional coagulative risk. Whether outside the hospital or when admitted, patients with inherited thrombophilia need special anticoagulant attention. Identifying such patients, especially in susceptible populations like the Egyptian people, will aid primary providers in risk stratification for choosing the optimal anticoagulation plan. Case-control study which will be conducted on 33 patients who had been diagnosed as COVID-19 at Ain-Shams University isolation Hospitals and 13 healthy controls. Patients will be subjected to: Thorough history taking, Thorough clinical assessment,COVID-19 PCR+/- radiological data collection, Assessment of MTHFR C677T genotypes were determined by RT- PCR of 2 ml EDTA blood sample, Follow up patient for 28 days as regard development of vascular thrombotic manifestation (D. dimer, LL duplex, or CT chest with Pulmonary angiography if needed).

Official Title
-----------------
Prevalence of Thrombophilic Gene Polymorphism (MTHFR C677T) in Egyptian Patients With COVID-19

Conditions
-----------------
COVID 19 Associated Coagulopathy

Intervention / Treatment
-----------------
* Diagnostic Test: RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All adult patients diagnosed as COVID -19 by RT-PCR will be included Exclusion Criteria: Patients younger than 18 years old Patients on Antithrombotic treatment before COVID-19.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group<br>Covid 19 patients in which MTHFR C677T genotypes was determined by RT- PCR of 2 ml EDTA blood sample.Follow up patient for 28 days as regard development of vascular thrombotic manifestation | Diagnostic Test: RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes<br>* Venous blood sample<br>|
| Control group<br>Healthy subjects in which MTHFR C677T genotypes was determined by RT- PCR of 2 ml EDTA blood sample. | Diagnostic Test: RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes<br>* Venous blood sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| development of vascular thrombotic manifestation | Level of D. dimer, Lower Limb duplex, or CT chest with Puplomary Angiography if needed. | 4 weeks |